Visterra (NASDAQ:VIST) Downgraded by Zacks Investment Research

Share on StockTwits

Zacks Investment Research downgraded shares of Visterra (NASDAQ:VIST) from a hold rating to a sell rating in a research report report published on Friday, Zacks.com reports.

According to Zacks, “Vista Oil & Gas, S.A.B. de C.V. is engaged in the energy sector. It focuses on the identification, acquisition and development of oil and gas fields primarily in Mexico, Argentina, Brazil and Colombia. Vista Oil & Gas, S.A.B. de C.V. is based in Mexico. “

Shares of VIST opened at $7.40 on Friday. The company has a 50 day simple moving average of $5.57. Visterra has a 52-week low of $3.80 and a 52-week high of $11.03.

Visterra (NASDAQ:VIST) last announced its quarterly earnings results on Tuesday, October 22nd. The biotechnology company reported $0.25 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.17 by $0.08. The company had revenue of $105.44 million during the quarter.

Several hedge funds and other institutional investors have recently bought and sold shares of VIST. Boston Partners acquired a new stake in Visterra during the 3rd quarter worth $5,067,000. Dean Capital Investments Management LLC purchased a new stake in Visterra in the third quarter valued at $341,000. Finally, FNY Investment Advisers LLC acquired a new position in Visterra in the third quarter valued at $27,000.

Visterra Company Profile

Visterra Inc is a United States-based biotechnology company. The Company uses its Atomic Interaction Network analysis to identify disease targets and design effective therapeutics. The Company’s technology is based on its Hierotope Platform, which identifies an area, or epitope, on the target protein, glycoprotein or glycan that is fundamental to its structure and function.

Further Reading: How to calculate the intrinsic value of a stock

Get a free copy of the Zacks research report on Visterra (VIST)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Visterra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Visterra and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2020 BBNS.